Cure My Disease

Don't miss your cure!

 Log in / Sign up

Skin gel targets immune signals in rare lymphoma

NCT ID NCT07714187

Not yet recruiting Disease control Sponsor: SecuraBio Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This early-phase trial tests a topical gel containing duvelisib, a drug that blocks certain immune signals, in people with early-stage mycosis fungoides — a type of skin lymphoma. The study enrolls about 30 participants with stage IA to IIA disease who have 3 to 5 accessible skin lesions. The main goals are to assess safety, local skin reactions, and find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a topical gel form of duvelisib, a drug that blocks certain immune signals
What this could lead to
If safe and effective, this gel could offer a targeted, skin-directed treatment option for early-stage mycosis fungoides, potentially reducing the need for systemic therapies.
What could go wrong
This is a very early, small phase 1 trial focused on safety and dosing, so it is not designed to prove efficacy. The gel may cause local skin reactions or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS T-CELL LYMPHOMA MYCOSIS FUNGOIDES

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University

    Baltimore, Maryland, 21218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.